Aristides Capital LLC bought a new position in shares of Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 27,000 shares of the company's stock, valued at approximately $325,000. Aristides Capital LLC owned about 0.08% of Delcath Systems at the end of the most recent quarter.
A number of other institutional investors have also modified their holdings of the business. Quantbot Technologies LP acquired a new position in Delcath Systems in the 4th quarter valued at about $66,000. Barclays PLC acquired a new position in shares of Delcath Systems in the third quarter valued at approximately $104,000. Jane Street Group LLC purchased a new stake in shares of Delcath Systems during the third quarter worth approximately $110,000. Private Advisor Group LLC acquired a new stake in shares of Delcath Systems during the fourth quarter worth $153,000. Finally, Charles Schwab Investment Management Inc. purchased a new position in Delcath Systems in the 4th quarter valued at $156,000. 61.12% of the stock is owned by institutional investors and hedge funds.
Delcath Systems Trading Up 1.2 %
Shares of DCTH traded up $0.13 during trading hours on Friday, reaching $10.66. The company had a trading volume of 371,703 shares, compared to its average volume of 352,162. Delcath Systems, Inc. has a 12-month low of $4.26 and a 12-month high of $16.97. The firm has a 50 day simple moving average of $13.59 and a 200-day simple moving average of $12.19. The company has a market capitalization of $356.40 million, a price-to-earnings ratio of -7.90 and a beta of 0.85.
Delcath Systems (NASDAQ:DCTH - Get Free Report) last released its quarterly earnings results on Thursday, March 6th. The company reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.01). Delcath Systems had a negative return on equity of 338.16% and a negative net margin of 150.70%. The firm had revenue of $15.10 million during the quarter, compared to analyst estimates of $14.96 million. During the same quarter in the prior year, the company earned ($0.48) EPS. Sell-side analysts forecast that Delcath Systems, Inc. will post -0.79 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of equities analysts have commented on the stock. HC Wainwright upped their price objective on shares of Delcath Systems from $22.00 to $24.00 and gave the stock a "buy" rating in a research report on Friday, March 7th. Craig Hallum raised their price objective on shares of Delcath Systems from $18.00 to $21.00 and gave the company a "buy" rating in a research report on Friday, January 17th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $22.75.
Check Out Our Latest Analysis on DCTH
About Delcath Systems
(
Free Report)
Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Recommended Stories
Before you consider Delcath Systems, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Delcath Systems wasn't on the list.
While Delcath Systems currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
